In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …

Background This guideline has been developed jointly by the European Society of
Haematology and International Society of Amyloidosis recommending non-transplant …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by
deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells …

The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …

Amyloid light chain (AL) amyloidosis is among the more common and more severe of the
amyloidoses usually involving the slow proliferation of a bone-marrow-residing plasma cell …

In 2012, the International Society of Amyloidosis (ISA) established the criteria for
assessment of haematologic response to treatment in light chain (AL) amyloidosis [1]. The …

The treatment of patients with systemic light chain (AL) amyloidosis is a challenge to
hematologists. Despite its generally small size, the underlying clone causes a rapidly …

Immunoglobulin light chain (AL) amyloidosis is a clonal plasma cell disorder leading to
progressive and life-threatening organ failure. The heart and the kidneys are the most …

Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range
proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy …